drugset / Trial / NCT00144651

Study of MRA in Patients With Rheumatoid Arthritis (RA)

NCT00144651

Phase 2 Completed 135 enrolled Chugai Pharmaceutical
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.

Timeline

Start
2001-08
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 8 mg/kg

Indications